Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AUROPHARMA.NSE
- Price
- 1082.45
- Stock movement up
- +24.45 (2.31%)
- Company name
- Aurobindo Pharma Limited
- Exchange
- (NSE ,
- Currency
- INR )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 628.69B
- Ent value
- 761.74B
- Price/Sales
- 2.09
- Price/Book
- 2.04
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 17.55
- Forward P/E
- 17.38
- PEG
- -
- EPS growth
- 6.06%
- 1 year return
- -3.67%
- 3 year return
- 14.50%
- 5 year return
- 23.65%
- 10 year return
- -0.61%
Last updated: 2025-04-12
DIVIDENDS
AUROPHARMA.NSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 17.55 |
| Price to OCF | 74.27 |
| Price to FCF | 74.27 |
| Price to EBITDA | 35.70 |
| EV to EBITDA | 43.25 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.09 |
| Price to Book | 2.04 |
| EV to Sales | 2.53 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 580.80M |
| EPS (TTM) | 61.35 |
| FCF per share (TTM) | 14.50 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 300.65B |
| Gross profit (TTM) | 147.13B |
| Operating income (TTM) | 60.93B |
| Net income (TTM) | 35.82B |
| EPS (TTM) | 61.35 |
| EPS (1y forward) | 62.29 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 48.94% |
| Operating margin (TTM) | 20.27% |
| Profit margin (TTM) | 11.91% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 39.04B |
| Net receivables | 0.00 |
| Total current assets | 262.26B |
| Goodwill | 6.30B |
| Intangible assets | 33.79B |
| Property, plant and equipment | 0.00 |
| Total assets | 480.94B |
| Accounts payable | 44.33B |
| Short/Current long term debt | 84.27B |
| Total current liabilities | 143.41B |
| Total liabilities | 172.09B |
| Shareholder's equity | 308.85B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 8.47B |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 8.47B |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 11.60% |
| Return on Assets | 7.45% |
| Return on Invested Capital | 9.65% |
| Cash Return on Invested Capital | 2.28% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1099.50 |
| Daily high | 1109.80 |
| Daily low | 1073.10 |
| Daily Volume | 1.56M |
| All-time high | 1568.05 |
| 1y analyst estimate | 1537.14 |
| Beta | 0.59 |
| EPS (TTM) | 61.35 |
| Dividend per share | - |
| Ex-div date | 20 Feb 2024 |
| Next earnings date | 23 May 2025 |
Downside potential
Loading...
Downside potential data
| AUROPHARMA.NSE | S&P500 | |
| Current price drop from All-time high | -30.97% | -12.89% |
| Highest price drop | -91.18% | -56.47% |
| Date of highest drop | 17 Sep 2001 | 9 Mar 2009 |
| Avg drop from high | -44.51% | -11.07% |
| Avg time to new high | 37 days | 12 days |
| Max time to new high | 2248 days | 1805 days |
COMPANY DETAILS
Marketcap
628.69B
Marketcap category
Large-cap
Description
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Employees
26015
Website
Investor relations
-
SEC filings
CEO
Country
India
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found